3463 results for «2023大国工匠年度人物»
3463 results
TAVI pathway optimisation in Europe, insights and evidence
29 Nov 2023 – From PCR London Valves 2023
In this roundtable, Francesco Saia, Derk Frank and Douglas Muir discuss the need for TAVI pathway optimisation and Edwards' clinical project called Benchmark program, which comprises the best practices based on the evidence regarding pre- peri-and post-procedural TAVI phases.
This interview was filmed at PCR London Valves...
How can the latest long-term TAVI evidence impact our daily decision-making?
Join Antoinette Neylon, Didier Tchétché and Ole De Backer as they discuss the key issues in terms of lifetime management of TAVI patients, the learnings from the 10-year TAVI NOTION, the 4-year Evolut Low Risk, and the impact on initial device choice.
This interview was filmed at...
Recent clinical evidence for mitral TEER the CLASP IID trial
06 Dec 2023 – From PCR London Valves 2023
What is the CLASP IID registry and what are the key learnings from 1-year data? Philipp Lurz and Jörg Hausleiter describe the methodology of the programme which compares Pascal vs Mitraclip in patients with degenerative mitral regurgitation. Discover the key findings which are relevant to your practice.
This...
Treating a wide range of patient anatomies with the PASCAL implants
06 Dec 2023 – From PCR London Valves 2023
Sam Dawkins, Niklas Schofer and Mirjam Wild share the latest experience on Pascal implants for mitral and tricuspid TEER. Together they discuss the rationale for using the same device for mitral and tricuspid, how the skills and knowledge on MR can be used for TR,...
DurAVR early safety and feasibility of a new class of biomimetic transcatheter aortic valve
05 Dec 2023 – From PCR London Valves 2023
DurAVR is a new TAVR valve which can mimic the shape of an original aortic valve. In this roundtable, Michael Reardon, Christopher Meduri, and Azeem Latib discuss this new technology, its key features, and the unmet medical needs it aims to answer. Find out more about...
The revolution coming to tricuspid valve treatment with the EVOQUE replacement system
06 Dec 2023 – From PCR London Valves 2023
Marianna Adamo and Philipp Lurz summarize the results of the TRISCEND II randomized trial which addresses the question of transcatheter tricuspid replacement (using the EVOQUE system) vs OMT. Find out more about the key findings at 6 months and the relevance for your practice
This interview was...
What does lifetime management mean for the valve patient?
10 Jan 2024 – From PCR London Valves 2023
Bettina Kirk, Alexandra Baer and John Webb discuss the question of lifetime management for valve disease patients, and begin by outlining the main difficulties involved, offering both an interventional cardiologist's and a nurse's perspective.
Then, they are considering how this lifetime management could be improved in the...
How to prepare an excellent abstract for EuroPCR?
17 May 2023 – From EuroPCR 2023
Marjo De Ronde asks Davide Capodanno, Chief Editor of the EuroIntervention Journal, to describe the main steps for nurses, allied health professionals and researchers to get started with research.
If motivation and passion are the key words, the starting point remains the idea, which must be relevant, and...
Implications of TRILUMINATE, a randomized clinical trial of transcatheter repair for tricuspid regurgitation
17 May 2023 – From EuroPCR 2023
Listen to Nicole Karam and Fabien Praz talk about the latest update from the TRILUMINATE study, the very first randomized trial conducted to determine how to improve the prognosis of tricuspid regurgitation.
To do so, the study aimed at comparing optimal medical treatment with interventions with edge-to-edge repair.
The content...
Latest on TAVI in complex bicuspid lesions
17 May 2023 – From EuroPCR 2023
The bicuspid aortic valve is a real challenge in terms of diagnosis and treatment of patients, as discussed by Didier Tchétché and Raj Makkar in this interview.
Given that there are different phenotypes and patterns of calcification, some patients should indeed not be treated by TAVI: find out...
Should we perform revascularisation in patients with depressed left ventricle ejection fraction?
17 May 2023 – From EuroPCR 2023
Divaka Perera, main author of the REVIVED study, discusses the results of this trial with Flavio Ribichini.
REVIVE was a trial of severe ischaemic cardiomyopathy in which the primary outcome was death or heart failure hospitalization.The headline result was that there was absolutely no difference with PCI,...
What are the essential skillsets for aspiring transcatheter edge-to-edge mitral valve repair operators?
17 May 2023 – From EuroPCR 2023
Rebecca Hahn, interventional echocardiographer, and Sam Dawkins, interventional cardiologist, look at the skills a good fellow needs to become an excellent interventional cardiologist, particularly in relation to mitral interventions.
Mastery of imaging and the three-dimensional nature of the heart seems to be the key to success, but...
What is the best contemporary interventional management of out-of-hospital cardiac arrest?
17 May 2023 – From EuroPCR 2023
Thomas Keeble and Marko Noc tackle the tricky question of how to deal with a patient with out-of-hospital cardiac arrest.
While STEMI patients should almost invariably go directly to the cathlab, the situation seems less clear-cut for non-ST-elevation patients, for whom a genuinely personalized approach needs to be proposed.
Study...
When to use drug coated balloons in de novo lesions?
What areas are most subject to drug-coated balloon angioplasty in de novo lesions? Fernando Alfonso and Robert Byrne provide some answers in this interview, in which they list the scenarios in which this technology appears attractive.
Small vessel disease, diffuse disease, STEMI, side-branches and patients at high-bleeding risk are...
When should we perform PCI for stable coronary artery disease in aortic stenosis, pre, post, never?
17 May 2023 – From EuroPCR 2023
What is the evidence for the need for PCI in patients with stable coronary artery disease and severe aortic stenosis? Is invasive angiography always mandatory for these patients? What about CT scans? When exactly should PCI be performed?
These are the questions Vijay Kunadian and Martine Gilard...
EuroPCR 2025 – Meta-Analysis of Individual Patient Data from the PROTECTED TAVR and BHF PROTECT-TAVI Trials
21 May 2025
Paris, France, 20-23 May 2025. The EuroPCR Course Directors have selected 3 major late-breaking trials that will be presented for the first time during the 2025 edition of EuroPCR. These trials were selected because of their design, results, and potential to impact practice, among which is the...
Results from the DCR4Contrast (Dynamic Coronary Roadmap for Contrast reduction) Trial
16 May 2023 – From EuroPCR 2023
Javier Escaned joins Ajay Kirtane to discuss the DCR4C Trial he conducted, and more specifically to present the main results.
The framework of the study was the contrast reduction during PCI, which is closely related to what is now known as ultra-low contrast PCI, and which mainly concerns particularly...
New developments in intravascular lithotripsy after 5 years of clinical practice
17 May 2023 – From EuroPCR 2023
Angela McInerney and James Spratt look back at 5 years of intravascular lithotripsy and how it has evolved from its beginnings to the present day.
Calcium has always been a very complex issue especially in older patients, but the tools to treat it were somewhat limited....
The CorFlow MOCA I Trial: learnings from the first-in-human direct measurement of microvascular obstruction in STEMI
16 May 2023 – From EuroPCR 2023
To help you better understand the MOCA I Late-Breaking clinical Trial and its findings, follow this exchange between Rob Schwartz, Marco Valgimigli, and Azeem Latib.
What is this study about? What technology are we talking about exactly? Why is it important for clinical practice? How can we...
The remaining big questions in transcatheter tricuspid valve intervention
18 Dec 2023 – From PCR London Valves 2023
Rebecca Hahn, Anita Asgar and Scott Lim discuss where management and treatment of tricuspid valve diseases stand today.
Even if the subject has finally found its place, a number of questions remain unanswered and deserve to be addressed: Who are the patients that should be treated with...
